Product Name |
Cyclophosphamide D8 |
Alternate Names |
Cyclophosphamide Stable Isotopes, Stable Isotopes of Cyclophosphamide |
CAT No. |
CS-O-06517
|
CAS No. |
1178903-96-2 |
Category |
Stable Isotopes |
Stock |
IN-Stock
|
Mol. Wt. |
269.14 g/mol |
Mol. For. |
C₇H₇D₈Cl₂N₂O₂P
|
Hazardous |
This is a Hazardous Compound
|
COA |
View Sample COA
|
MSDS |
View Sample MSDS
|
Parent API |
Cyclophosphamide |
Purity |
95% |
Therapeutic |
Immunosuppressants |
Smileys |
O=[P]1(NCCCO1)N(C([2H])([2H])C([2H])([2H])Cl)C([2H])([2H])C([2H])([2H])Cl |
Controlled |
No |
Shipping |
Free for purchase above 1000$ |
Delivery |
In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
Return |
Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
Ordering |
Place your order online or by email sales@clearsynth.com |
If you find a better price anywhere else we guarantee Price match.
Cyclophosphamide D8 is a deuterated derivative of cyclophosphamide, which is a synthetic alkylating agent used in chemotherapy to treat various types of cancer. Cyclophosphamide D8 is specifically used in pharmacokinetic and metabolic studies to understand the pharmacological effects of cyclophosphamide on the body.
Cyclophosphamide D8 is a prodrug that is metabolized in the liver by the cytochrome P450 enzyme system to form its active metabolites. The deuterium labeling in Cyclophosphamide D8 allows for the tracking of the drug's metabolic fate and provides insight into the drug's pharmacokinetics.
Cyclophosphamide D8 is administered intravenously or orally depending on the type of cancer being treated. It is used in the treatment of various types of cancer, including breast cancer, leukemia, lymphoma, and multiple myeloma. It works by interfering with the DNA synthesis of cancer cells, leading to their death.
However, like all chemotherapy drugs, Cyclophosphamide D8 has potential side effects. These include nausea, vomiting, hair loss, decreased appetite, and lowered immune function. Patients receiving Cyclophosphamide D8 are closely monitored for these side effects and treated accordingly.
In conclusion, Cyclophosphamide D8 is an important tool in cancer research and treatment. Its deuterium labeling provides valuable information on the drug's pharmacokinetics and metabolic fate, aiding in the development of more effective cancer treatments.